SCHEMBL4258736

SCHEMBL4258736

Cc1cc(NC2CCC(NC(=O)c3cc(Br)cc(Br)c3)CC2)nc(N(C)C)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.48
KCNH2 Q12809 1/20 0.48
AURKB Q96GD4 1/20 0.48
MCHR1 Q99705 17/20 0.48
ADRA2A P08913 8/20 0.48
HRH1 P35367 7/20 0.48
ADRA1A P35348 4/20 0.48
HTR2B P41595 6/20 0.47
TUBB4A P04350 1/20 0.44
TUBB P07437 1/20 0.44
TUBA3C P0DPH7 1/20 0.44
TUBA1B P68363 1/20 0.44
TUBA4A P68366 1/20 0.44
TUBB4B P68371 1/20 0.44
TUBB3 Q13509 1/20 0.44
TUBB2A Q13885 1/20 0.44
TUBB8 Q3ZCM7 1/20 0.44
TUBA3E Q6PEY2 1/20 0.44
TUBA1A Q71U36 1/20 0.44
TUBA1C Q9BQE3 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4258733 1.00 CNR1 (0.48) CNR1KCNH2AURKBMCHR1ADRA2A
SCHEMBL4263042 0.89 SMYD3 (0.56) CNR1KCNH2AURKBMCHR1ADRA2A
SCHEMBL4263046 0.89 SMYD3 (0.56) CNR1KCNH2AURKBMCHR1ADRA2A
SCHEMBL4270962 0.85 MCHR1 (0.56) CNR1KCNH2AURKBMCHR1ADRA2A
SCHEMBL4270965 0.85 MCHR1 (0.56) CNR1KCNH2AURKBMCHR1ADRA2A
SCHEMBL4256756 0.84 CNR1 (0.54) CNR1KCNH2AURKBMCHR1ADRA2A
SCHEMBL4256768 0.84 CNR1 (0.54) CNR1KCNH2AURKBMCHR1ADRA2A
SCHEMBL4266460 0.84 MCHR1 (0.68) CNR1KCNH2AURKBMCHR1ADRA2A
SCHEMBL4266457 0.84 MCHR1 (0.68) CNR1KCNH2AURKBMCHR1ADRA2A
SCHEMBL4260785 0.83 MCHR1 (0.67) CNR1KCNH2AURKBMCHR1ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090036448-A1 PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMECUTICAL CO., LTD. (JP) 2009-02-05 US claimed
US-20090036448-A1 PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMECUTICAL CO., LTD. (JP) 2009-02-05 US disclosed
EP-1730122-A2 PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO., LTD (JP) 2006-12-13 EP disclosed
WO-2005095357-A2 PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO., LTD. (JP) 2005-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036448-A1 PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF GPR119, HCRTR2, MCHR1 CNR1 114/4885KCNH2 3317/4885AURKB 1199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.